期刊文献+

洛铂对肺癌HTB-56、HTB-56/DDP细胞株生长抑制作用的研究 被引量:8

Research on growth inhibitoty of HTB-56 cells and HTB-56/DDP cells in lung cancer treated with lobaplatin
原文传递
导出
摘要 目的探讨不同浓度洛铂(LBP)对肺癌HTB-56、HTB-56/DDP细胞株生长抑制作用的影响,及不同药物浓度对细胞影响之间的关系。方法选择人肺癌HTB-56及其耐DDP细胞株HTB-56/DDP为研究对象,用MTT比色法检测不同浓度LBP作用于腺癌细胞株不同时间的OD值(optical density,光密度),比较药物剂量与其生长抑制效应之间的关系。结果 LBP能够抑制肺癌细胞株HTB-56及其耐DDP细胞株HTB-56/DDP的生长,并呈浓度与时间的依赖关系,随着浓度的升高和时间的延长对两种细胞的抑制率也随之增大。结论 LBP能够显著的抑制HTB-56及其耐DDP细胞株HTB-56/DDP的细胞增殖,并不与DDP交叉耐药。随着小剂量LBP作用时间的延长,细胞的生长抑制呈现浓度与时间的依赖。 Objective To discuss the effect on growth inhibitoty of lung adenocarcinoma cell treated by lobaplatin (LBP) in different doses, and the relationship between the effects and diverse doses. Methods Human lung adenocarcinoma cell lines HTB-56 and HTB-56/DDT cell lines were treated with different doses and lasting time of LBP to measure the OD (optical density) at different time by MTT, compare the relationships between dose of LBP and the growth control effect. Results LBP can control growth of lung adenocarcinoma cell lines HTB-56 and HTB-56/DDT cell lines which relate to dose and enduring time, control rate was upgrading with the increasing of the dose of LBP and time lasting. Conclusions LBP can control the growth of lung adenocarcinoma cell lines HTB-56 and HTB-56/DDT cell lines. Make sure LBP isn’t cross resistance with DDP. Growth control of lung adenocarcinoma cell related to the dose and enduring time when the continuous low dose of LBP treatment was lasting.
出处 《中华肺部疾病杂志(电子版)》 CAS 2012年第2期33-35,共3页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 CSCO-金港榄香烯肿瘤学研究生奖学助学基金(J-2010-008)
关键词 支气管肺癌 HTB-56、HTB-56/DDP细胞株 洛铂 MTT Bronchogenic carcinoma HTB-56 HTB-56/DDP cells line Lobaplatin MTT
  • 相关文献

参考文献6

二级参考文献23

  • 1Le Chevalier T. For the IAL T Investigators. Result s of the Randomized International Adjuvant Lung Cancer Trial ( IAL T) : cisplatin -based chemotherapy (CT) vs no CT in 1867 patient s (pts) with resected non -small cell lung cancer (NSCLC) [ J]. Proc Am Soc Clin Oncol,2003,23:6a.
  • 2Winton TL, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage Ⅰb and Ⅱ non -small cell lung cancer[ C]. New Orleans 40th Annal Meeting of the American Society of Clinical Oncology,2004,7018.
  • 3Strauss GM, Hemdon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resected in stage Ⅰb non - small cell lung cancer ( NSCLC ) : report of Cancer and Leukemia Group B ( CALGB ) protocol 9633 [ J]. J Clin Oncol,2004,22 ( Suppl 14S) : 612.
  • 4Douillard JY, Rosell R, Delena M, et al. Phase Ⅲ adjuvant vinorelbine and cisplatin versus observation in completely resected ( stage Ⅰ - Ⅲ ) non - small cell lung cancer patients: final results after 70 - month median followup [ J ]. J Clin Oncol, 2005,23 ( Suppl 16s) : 624.
  • 5Pisters K , Vallieres E, Bunn PA, et al. Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin(PC) chemotherapy in early stage non- small cell lung cancer (NSCLC) :Follow -up on a phase Ⅲ trial [ J]. J Clin Oncol,2007.25 (18s) :7520.
  • 6Scagliotti G, Pastorino U, Vansteenkiste J, et al. A phase Ⅲ randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early - stage non - small cell lung cancer (NSCLC) : Follow - up data of Ch.E. S. T [ J ]. J Clin Oncol, 2008,26:7508.
  • 7Nieolson M, Gilligan D, Smith I, et al. Pre - operative chemotherapy in patients with resectable non - small cell lung cancer (NSCLC) : First results of the MRC LU22/NVALT/EORTC 08012 multi - centre randomised trial [ J ]. J Clin Oncal, 2007, 25 (18suppl) : 7518.
  • 8Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non - small cell lung cancer [J]. N Engl J ned,2002,346:92 -98.
  • 9Shepherd FA, Daneey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non - small cell lung cancer previously treated with platinum - based chemotherapy[J]. J Clin Oncol,2000,18(10) : 2095 -2103.
  • 10Gefitinib(Iressa) Lung Cancer ISEL trial shows no overall suivival advantage in a highly refractory population[ J]. Astrazeneca Press Relesase, 2004.

共引文献68

同被引文献136

  • 1全吉钟,冯燕,王冬旭,黄京子.吉西他滨联合洛铂或顺铂一线治疗老年晚期非小细胞肺癌患者的疗效[J].中国老年学杂志,2014,34(5):1181-1182. 被引量:32
  • 2李琳琳,马锐,岳峥,刘文静.洛铂联合紫杉醇治疗晚期非小细胞肺癌近期疗效和安全性分析[J].中国实用内科杂志,2009,29(S2):90-91. 被引量:3
  • 3杨柳青,施毅,秦叔逵,钱军,韩宝惠,潘良熹,马胜林,李恩孝,蔡光蓉,李园,于国华,杨俊兰,王华庆,储大同.洛铂联合长春瑞滨治疗晚期非小细胞肺癌的临床研究[J].临床肿瘤学杂志,2006,11(12):890-894. 被引量:39
  • 4McKeage MJ. Lobaplatin: a new antitumour platinum drug [ J ]. Expert Opin Investig Drugs, 2001, 10( 1 ) : 119-128.
  • 5Kairi JK, Toth JW, Gusani N J, et al. Muhidisciplinary management of malignant pleural effusion [ J ]. J Surg Oncol, 2012,105 ( 7 ) : 731-738.
  • 6Katzenstein HM, Petricca S, Olson TA, et al. Intracavitary cisplatin therapy for pediatric malignancies[J]. Pediatr Blood Cancer, 2010, 55(3) : 452-456.
  • 7Perabo FG, Mtlller SC. New agents for treatment of advanced transitional cell carcinoma[J]. Ann Oncol, 2007, 18(5): 835.
  • 8Wang Z, Tang X, Yang X, et al. Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE[J]. Biomed Pharmacother, 2012, 66(3) : 161-166.
  • 9Dai HY, Liu L, Li SY, et al. Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell Line LOVO in vitro [ J]. Biomed Pharmacother, 2011, 65 ( 3 ) : 137- 141.
  • 10Engel JB, Martens T, Honig A, et al. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple- negative p53-mutated breast cancers in vitro[ J]. Anticancer Drugs, 2012, 23(4) : 426-436.

引证文献8

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部